Researchers: No vaccine efficacy registered in HIV vaccine trial
The Prepvacc HIV prevention study of experimental vaccine regimens and a new form of oral pre-exposure prophylaxis (PrEP) running in East and Southern Africa among 1,500 volunteer participants has stopped further vaccinations, as there is little or no chance of the trial demonstrating vaccine efficacy in preventing HIV acquisition. Enrollment of healthy adults aged between 18 and 40 in PrepVacc began in December 2020 and was completed on 1st March 2023 with 1,512 participants. Tonight, Walter Mwesigye speaks to the Chief Investigator, Professor Pontiano Kaleebu, about this development.
